Synergistic Effect Of A Retinoid X Receptor-Selective Ligand Bexarotene And Docetaxel In Prostate Cancer [Corrigendum]
Shen D, Wang H, Zheng Q, et al. Onco Targets Ther. 2019;12:7877–7886. Upon reviewing the article, the authors noticed an error in two of the authors name (page 7877). The correct author ames are Liqun Xia and Gonghui Li. The authors apologize for this...
Main Authors: | Shen D, Wang H, Zheng Q, Cheng S, Xu L, Wang M, Li GH, Xia L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-10-01
|
Series: | OncoTargets and Therapy |
Online Access: | https://www.dovepress.com/httpswwwdovepresscomcorrigendum-synergistic-effect-of-a-ret-peer-reviewed-article-OTT |
Similar Items
-
Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer
by: Shen D, et al.
Published: (2019-09-01) -
Synergistic Effects of PPARγ Ligands and Retinoids in Cancer Treatment
by: Masahito Shimizu, et al.
Published: (2008-01-01) -
Of Retinoids and Organotins: The Evolution of the Retinoid X Receptor in Metazoa
by: Elza Fonseca, et al.
Published: (2020-04-01) -
Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats
by: Yuchun Zuo, et al.
Published: (2019-02-01) -
Bexarotene and Hypopituitarism
by: Hulusi Atmaca, MD, et al.
Published: (2015-01-01)